|
Volume
7 Number 4
April 2019
|
|
Home
>
Disciplines
>
Publications
>
Prostate
Cancer Research
>
Volume
7, Year 2019
>
Number 4, April
|
|
|
CONTENTS
|
▼
|
|
CASE
REPORTS
DIAGNOSIS
EPIDEMIOLOGY,
RISK FACTORS, PREVENTION
ETIOLOGY,
PATHOGENESIS, PATHOLOGY
FOLLOW-UP,
QUALITY OF LIFE
INTEGRATIVE
MEDICINE
PROGNOSIS
TREATMENT
|
|
|
CASE
REPORTS
|
▲
|
.
|
Vaishampayan U, Shi D, Abdulfatah E, Aoun H, Wynberg J.
Exceptional pathologic complete response achieved with
androgen deprivation and docetaxel therapy in Gleason 10 prostate
cancer.
Urol Case Rep. 2019 Jan 28;23:103-105. doi:
10.1016/j.eucr.2019.01.018. eCollection 2019 Mar.
Source
.
Similar
articles
|
|
|
DIAGNOSIS
|
▲
|
.
|
Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S.
Clinicopathological predictors of positive 68Ga-PSMA-11
PET/CT in PSA-only recurrence of localized prostate cancer
following definitive therapy.
Ann Nucl Med. 2019 Feb 18.
doi: 10.1007/s12149-019-01340-1. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
.
|
Houlahan KE, Salmasi A, Sadun TY, Pooli A, Felker ER, Livingstone
J, Huang V, Raman SS, Ahuja P, Sisk AE Jr, Boutros PC, Reiter RE.
Molecular Hallmarks of Multiparametric Magnetic Resonance
Imaging Visibility in Prostate Cancer.
Eur Urol. 2019
Jan 24. pii: S0302-2838(18)31044-3. doi:
10.1016/j.eururo.2018.12.036. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
.
|
Kam J, Yuminaga Y, Krelle M, Gavin D, Koschel S, Aluwihare K,
Sutherland T, Skinner S, Brennan J, Wong LM, Louie-Johnsun M.
Evaluation of the accuracy of multiparametric MRI for
predicting prostate cancer pathology and tumour staging in the
real world: an australian multicentre study.
BJU
Int. 2019 Feb 3. doi: 10.1111/bju.14696. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
.
|
Shoag JE, Tosoian JJ, Salami SS, Barbieri CE.
Unraveling
Prostate Cancer Genomics, Pathology, and Magnetic Resonance
Imaging Visibility.
Eur Urol. 2019 Jan 31. pii:
S0302-2838(19)30070-3. doi: 10.1016/j.eururo.2019.01.027. [Epub
ahead of print]
Source
.
Similar
articles
Referring
to: Houlahan KE et al., Molecular Hallmarks of Multiparametric
Magnetic Resonance Imaging Visibility in Prostate Cancer. Eur
Urol. 2019 Jan 24. pii: S0302-2838(18)31044-3. doi:
10.1016/j.eururo.2018.12.036. [Epub ahead of print]. Source
.
|
|
|
.
|
Welch BT, Packard AT, Atwell TD, Johnson GB, Lowe VJ, Karnes RJ,
Mynderse LA, Gunderson TM, Park SS, Stish BJ, Evans JD, Kwon ED,
Davis BJ, Nathan MA.
Percutaneous Image-Guided Nodal
Biopsy After 11C-Choline PET/CT for Biochemically Recurrent
Prostate Cancer: Imaging Predictors of Disease and Clinical
Implications.
Adv Radiat Oncol. 2018 Sep 4;4(1):79-89.
doi: 10.1016/j.adro.2018.08.022. eCollection 2019 Jan-Mar.
Source
.
Similar
articles
|
|
|
EPIDEMIOLOGY,
RISK FACTORS, PREVENTION
|
▲
|
.
|
De Nunzio C, Brassetti A, Simone G, Lombardo R, Mastroianni R,
Collura D, Muto G, Gallucci M, Tubaro A.
Metabolic
syndrome increases the risk of upgrading and upstaging in patients
with prostate cancer on biopsy: a radical prostatectomy
multicenter cohort study.
Prostate Cancer Prostatic Dis.
2018 Sep;21(3):438-445. doi: 10.1038/s41391-018-0054-9. Epub 2018
Jun 4. Erratum
in: Prostate Cancer Prostatic Dis. 2019 Feb 1. .
Source
.
Similar
articles
|
|
|
.
|
Ho W, Choo DW, Wu YJ, Chan TF, Lin ZF.
Statins Use and
the Risk of Prostate Cancer in Ischemic Heart Disease Patients in
Taiwan.
Clin Pharmacol Ther. 2019 Feb 22. doi:
10.1002/cpt.1408. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
.
|
Yoo S, Oh S, Park J, Cho SY, Cho MC, Son H, Jeong H.
Effects
of metabolic syndrome on the prevalence of prostate cancer:
historical cohort study using the national health insurance
service database.
J Cancer
Res Clin Oncol. 2019 Mar;145(3):775-780. doi:
10.1007/s00432-019-02842-1. Epub 2019 Jan 17.
Source
.
Similar
articles
|
|
|
ETIOLOGY,
PATHOGENESIS, PATHOLOGY
|
▲
|
.
|
Wang W, Yang X, Dai J, Lu Y, Zhang J, Keller ET.
Prostate
cancer promotes a vicious cycle of bone metastasis progression
through inducing osteocytes to secrete GDF15 that stimulates
prostate cancer growth and invasion.
Oncogene. 2019 Feb
12. doi: 10.1038/s41388-019-0736-3. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
FOLLOW-UP,
QUALITY OF LIFE
|
▲
|
.
|
Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E,
Wagland R, Kind P, Donnelly DW, Butcher H, Catto JWF, Cross W,
Mason M, Sharp L, Weller D, Velikova G, McCaughan E, Mottram R,
Allen M, Kearney T, McSorley O, Huws DW, Brewster DH, McNair E,
Gavin A, Glaser AW.
Quality of life in men living with
advanced and localised prostate cancer in the UK: a
population-based study.
Lancet Oncol. 2019
Mar;20(3):436-447. doi: 10.1016/S1470-2045(18)30780-0. Epub 2019
Jan 31.
Source
.
Similar
articles
|
|
|
.
|
Manfredi M, Checcucci E, Fiori C, Garrou D, Aimar R, Amparore D,
De Luca S, Bombaci S, Stura I, Migliaretti G, Porpiglia F.
Total
anatomical reconstruction during robot-assisted radical
prostatectomy: focus on urinary continence recovery and related
complications after 1000 procedures.
BJU Int. 2019 Feb
23. doi: 10.1111/bju.14716. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
.
|
Saad F.
Quality of life in men with prostate cancer.
Lancet Oncol. 2019 Mar;20(3):325-326. doi:
10.1016/S1470-2045(18)30863-5. Epub 2019 Jan 31.
Source
.
Similar
articles
Referring
to: Downing A et al., Quality of life in men living with advanced
and localised prostate cancer in the UK: a population-based study.
Lancet Oncol. 2019 Mar;20(3):436-447. doi:
10.1016/S1470-2045(18)30780-0. Epub 2019 Jan 31.
Source
.
|
|
|
INTEGRATIVE
MEDICINE
|
▲
|
.
|
Slade AN.
Prostate cancer and subsequent nutritional
outcomes: the role of diagnosis and treatment.
J Cancer
Surviv. 2019 Feb 7. doi: 10.1007/s11764-019-00739-z. [Epub ahead
of print]
Source
.
Similar
articles
|
|
|
.
|
Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R,
Porter LH, Niranjan B, Whitby ST, Lo J, Huang C, Schittenhelm RB,
Anderson KE, Furic L, Wijayaratne PR, Matzaris M, Montgomery MK,
Papargiris M, Norden S,
Suppressing fatty acid uptake has
therapeutic effects in preclinical models of prostate cancer.
Sci Transl Med. 2019 Feb 6;11(478). pii: eaau5758. doi:
10.1126/scitranslmed.aau5758.
Source
.
Similar
articles
|
|
|
PROGNOSIS
|
▲
|
.
|
Abdel-Rahman O.
Outcomes of Prostatectomy versus
Radiation Therapy in the Management of Clinically Localized
Prostate Cancer Patients Within the PLCO Trial.
Clin
Genitourin Cancer. 2019 Jan 4. pii: S1558-7673(19)30004-7. doi:
10.1016/j.clgc.2018.12.010. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
.
|
Bravi CA, Tin A, Vertosick E, Mazzone E, Martini A, Dell'Oglio P,
Stabile A, Gandaglia G, Fossati N, Suardi N, Gallina A, Briganti
A, Montorsi F, Vickers A.
The Impact Of Experience On The
Risk Of Surgical Margins And Biochemical Recurrence After
Robot-Assisted Radical Prostatectomy: A Learning-Curve Study.
J
Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000147. [Epub ahead of
print] -
Source
.
Similar
articles
|
|
|
.
|
Casale P, Saita A, Lazzeri M, Lughezzani G, Hurle R, Fasulo V,
Mondellini GM, Paciotti M, Domanico L, Lista G, Maffei D, Monari
M, Motta L, Bini V, Ceriotti F, Guazzoni G, Buffi N.
[-2]proPSA
for predicting biochemical recurrence of prostate cancer earlier
than total PSA after radical prostatectomy: an observational
prospective cohort study.
Minerva Urol Nefrol. 2019 Jan
28. doi: 10.23736/S0393-2249.19.03279-X. [Epub ahead of print]
-
Source
.
Similar
articles
|
|
|
.
|
Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER,
Chittoria N, Twardowski P, Vaishampayan U, Agarwal N.
Time
from definitive therapy to onset of metastatic disease predicts
outcomes in men with metastatic hormone sensitive prostate cancer.
Urol Oncol. 2019 Feb 13. pii: S1078-1439(19)30050-X.
doi: 10.1016/j.urolonc.2019.01.029. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
.
|
Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu
FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung
P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N,
Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG,
Steinberg ML, Kupelian PA, King CR.
Long-term Outcomes of
Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk
Prostate Cancer.
JAMA Netw Open. 2019 Feb
8;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006.
Source
.
Similar
articles
|
|
|
.
|
Peng C, Zhang J, Hou J.
Performance characteristics of
prostate-specific antigen density and biopsy primary Gleason score
to predict biochemical failure in patients with intermediate
prostate cancer who underwent radical prostatectomy.
Cancer
Manag Res. 2019 Feb 1;11:1133-1139. doi: 10.2147/CMAR.S190443.
eCollection 2019.
Source
.
Similar
articles
|
|
|
.
|
Porcaro AB, Tafuri A, Sebben M, Cacciamani G, Ghimenton C,
Brunelli M, Petrozziello A, Monaco C, Migliorini F, Siracusano S,
Artibani W.
Low Preoperative Prolactin Levels Predict
Non-Organ Confined Prostate Cancer in Clinically Localized
Disease.
Urol Int. 2019 Feb 14:1-9. doi:
10.1159/000496833. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
.
|
Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M,
Huland H, Tilki D.
Persistent Prostate-Specific Antigen
After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Eur Urol. 2019 Feb 13. pii: S0302-2838(19)30094-6. doi:
10.1016/j.eururo.2019.01.048. [Epub ahead of print]
Source
.
Similar
articles
|
|
|
TREATMENT
|
▲
|
.
|
Burki T.
Darolutamide for non-metastatic,
castration-resistant prostate cancer.
Lancet Oncol. 2019
Mar;20(3):e139. doi: 10.1016/S1470-2045(19)30102-0. Epub 2019 Feb
21.
Source
.
Similar
articles
Referring
to: Fizazi K et al., Darolutamide in Nonmetastatic,
Castration-Resistant Prostate Cancer. N Engl J Med. 2019 Feb 14.
doi: 10.1056/NEJMoa1815671.
[Epub
ahead of print] Source
.
|
|
|
.
|
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S,
Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A,
Sarapohja T, Smith MR; ARAMIS Investigators.
Darolutamide
in Nonmetastatic, Castration-Resistant Prostate Cancer.
N
Engl J Med. 2019 Feb 14. doi: 10.1056/NEJMoa1815671. [Epub ahead
of print]
Source
.
Similar
articles
|
|
|
bottom
|
▲
|
|
|